Personal Care Stocks Q1 Teardown: Coty (NYSE:COTY) Vs The Rest Earnings results often indicate what direction a company will take in the months ahead. With Q1 now behind us, let’s have a look at Coty (NYSE:COTY) and its peers. While personal care products products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering. Consumer tastes are constantly changing, and personal care companies are currently responding to the public’s increased desire for ethically produced goods by featuring natural ingredients in their products. The 13 personal care stocks we track reported a mixed Q1; on average, revenues beat analyst consensus estimates by 1.1%. while next quarter's revenue guidance was 7.5% below consensus. Stocks--especially those trading at higher multiples--had a strong end of 2023, but 2024 has seen periods of volatility. Mixed signals about inflation have led to uncertainty around rate cuts, and personal care stocks have had a rough stretch, with share prices down 6.5% on average since the previous earnings results. Coty (NYSE:COTY) With a portfolio boasting many household brands, Coty (NYSE:COTY) is a beauty products powerhouse with offerings in cosmetics, fragrances, and skincare. Coty reported revenues of $1.39 billion, up 7.5% year on year, in line with analysts' expectations. It was a mixed quarter for the company: Coty narrowly topped analysts' revenue and gross margin expectations. On the other hand, its operating margin missed analysts' expectations and its EPS missed Wall Street's estimates. Coty Total Revenue The stock is down 12.9% since the results and currently trades at $10.03. Read our full report on Coty here, it's free. Best Q1: The Honest Company (NASDAQ:HNST) Co-founded by actress Jessica Alba, The Honest Company (NASDAQ:HNST) sells diapers and wipes, skin care products, and household cleaning products. The Honest Company reported revenues of $86.22 million, up 3.4% year on year, outperforming analysts' expectations by 3.5%. It was a stunning quarter for the company, with an impressive beat of analysts' revenue and earnings estimates. The Honest Company Total Revenue The stock is down 0.7% since the results and currently trades at $2.92. Is now the time to buy The Honest Company? Access our full analysis of the earnings results here, it's free. Weakest Q1: Medifast (NYSE:MED) Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE:MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods. Medifast reported revenues of $174.7 million, down 49.9% year on year, in line with analysts' expectations. It was a weak quarter for the company, with revenue guidance for next quarter missing analysts' expectations and a miss of analysts' operating margin estimates. Medifast had the slowest revenue growth in the group. The stock is down 38.6% since the results and currently trades at $21.79. Read our full analysis of Medifast's results here. Herbalife (NYSE:HLF) With the first products sold out of the trunk of the founder’s car, Herbalife (NYSE:HLF) today offers a portfolio of shakes, supplements, personal care products, and weight management programs to help customers reach their nutritional and fitness goals. Herbalife reported revenues of $1.26 billion, flat year on year, falling short of analysts' expectations by 0.1%. It was a slower quarter for the company, with a miss of analysts' organic revenue growth estimates. The stock is up 19.6% since the results and currently trades at $10.39. Read our full, actionable report on Herbalife here, it's free. e.l.f. (NYSE:ELF) e.l.f. Beauty (NYSE:ELF), which stands for ‘eyes, lips, face’, offers high-quality beauty products at accessible price points. e.l.f. reported revenues of $321.1 million, up 71.4% year on year, surpassing analysts' expectations by 9.8%. It was a slower quarter for the company, with a miss of analysts' operating margin estimates and underwhelming earnings guidance for the full year. e.l.f. delivered the biggest analyst estimates beat and fastest revenue growth, but had the weakest full-year guidance update among its peers. The stock is up 36.9% since the results and currently trades at $212.98. Read our full, actionable report on e.l.f. here, it's free. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.
Personal Care Stocks Q1 Teardown: Coty (NYSE:COTY) Vs The Rest
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...